Emisphere Technologies, Inc. (OTC BB: EMIS) and Novo Nordisk A/S (NYSE: NVO) today announced that they have entered into an exclusive Development and Licence Agreement to develop and commercialise oral formulations of Novo Nordisk’s insulins, which have the potential of treating diabetes, using Emisphere’s Eligen® Technology.
http://www.novonordisk.com/press/se...8ca-9310-2930c1fa88d5&sShowLanguageCode=en-GB
http://www.novonordisk.com/press/se...8ca-9310-2930c1fa88d5&sShowLanguageCode=en-GB
